[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640857":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":32,"responsibleParty":60,"collaborators":22,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":22,"enrollmentInfo":72,"targetDuration":22,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":84,"whyStopped":22,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Centre Jean Perrin","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rheumatoid arthritis","EXPERIMENTAL","99mTc-NTP 15-5 at a diagnostic activity of 15 MBq\u002Fkg",[13],"Drug: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq\u002Fkg",{"label":15,"type":10,"description":11,"interventionNames":16},"digital osteoarthritis",[13],[18],{"type":19,"name":11,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq\u002Fkg (D0)",[9,15],null,[24],{"name":25,"affiliation":5,"role":26},"Marion CHANCHOU, Dr","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":22,"email":31},"CONTACT","33473278089","marion.chachou@clermont.unicancer.fr",[33,50],{"facility":5,"status":22,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Clermont-Ferrand","PUY DE DOME","63011","France","FR",{"type":40,"coordinates":41},"Point",[42,43],3.08682,45.77969,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":48,"phoneExt":22,"email":49},"MARION CHANCHOU, MD","04 73 27 82 01","Marion.chanchou@clermont.unicancer.fr",{"facility":51,"status":22,"city":34,"state":22,"zip":22,"country":37,"countryCode":38,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"Chu Clermont Ferrand",{"type":40,"coordinates":53},[42,43],{"lat":43,"lon":42},[56],{"name":57,"role":29,"phone":58,"phoneExt":22,"email":59},"SYLVAIN MATHIEU","MD","smathieu@chu-clermontferrand.fr",{"type":61,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100640857","phase-2-functional-imaging-of-digital-osteoarthritis-and-rheumatoid-arthritis-using-99mtc-ntp-15-5-in-nuclear-medicine-100640857",false,"NCT07624994","Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine","Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study","CARSPECT II","Inclusion Criteria:\n\n* Karnofsky index \\> 70%\n* Obtaining written, signed and dated informed consent\n* Affiliation to a health insurance plan\n* For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.\n* Ability and willingness to respect study visits, exams as well as protocol.\n\nRA Group:\n\n* certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR\u002FEULAR criteria,\n* symptomatic (finger pain \\> 4 \u002F10 on a numerical scale),\n* active synovitis (clinical and ultrasound),\n\nGroup DOA:\n\n* certain diagnosis of symptomatic DOA less than 5 years old (finger pain \\> 4 \u002F10 on a numerical scale),\n* stopping NSAIDs for at least 8 days before the injection,\n\nExclusion Criteria:\n\n* Ongoing use of non-steroidal anti-inflammatory drugs,\n* Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,\n* History of osteoarticular hand surgery.\n* History of hand soft tissue surgery in the past 6 months\n* Patients or patients 18 years old,\n* Pregnant or breastfeeding patient,\n* IMC\\>30,\n* History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,\n* Persons deprived of their liberty, under guardianship\u002Fcuratorship, or safeguarding of justice,\n* Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study.\n\nRA Group:\n\n* Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.\n* Patients with a history of hand DOA","ALL","18 Years",{"count":73,"type":74},80,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis",[80],"Digital Osteoarthritis or Rheumatoid Arthritis",[82,83],"proteoglycan tracer","cartilage","NOT_YET_RECRUITING","2026-06-03",{"date":87,"type":88},"2026-06-04","ACTUAL",{"date":90,"type":74},"2026-06-01",{"date":92,"type":74},"2028-07-01",{"name":5,"class":6},2]